- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00609999
Ph I Dasatinib + Erlotinib in Recurrent MG
Phase I Study of Dasatinib Plus Erlotinib in Recurrent Malignant Glioma
Primary:
To determine maximum tolerated dose & dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG
Secondary:
To further evaluate safety & tolerability of dasatinib + erlotinib To evaluate pharmacokinetics of dasatinib when administered w erlotinib among recurrent MG pts who are on & not on CYP-3A enzyme inducing anti-epileptic drugs To evaluate for anti-tumor activity with this regimen in this patient population
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Tarceva administered on continuous oral dosing schedule at 150 mg/day for pts not on EIAEDs & 450 mg/day for pts on EIAEDs. Starting dose level of dasatinib will be 100 mg once day via continuous oral daily dosing. Dasatinib will be increased in successive cohorts of enrolled pts. Pts will remain on treatment until excessive toxicity, progressive disease, withdrawal of consent/death.
Pts have confirmed diagnosis of recurrent/progressive WHO gr IV MG / WHO grade III MG. Phase I 3+3 dose escalation design w 2 independently escalated stratum: stratum A-pts not on CYP3A-enzyme inducing anti-epileptic drugs; stratum B-pts on EIAEDs. Assessment of safety will be based mainly on frequency of adverse events, particularly adverse events leading to discontinuation of treatment & on number of significant lab abnormalities.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke University Health System
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of recurrent/progressive WHO grade IV MG or WHO grade III MG. Pts with prior low-grade glioma are eligible if histologic assessment demonstrates transformation to WHO grade III / IV MG
- >18 yrs
- Karnofsky Performance Status >70 percent
- Pts presenting in 1st, 2nd / 3rd relapse. Prior therapy must have included external beam XRT
- Adequate bone marrow, liver & renal function as assessed by following:
- Hemoglobin>9.0g/dl
- ANC>1,500/mm3
- Platelet count>100,000/mm3
- Total bilirubin<1.5 x ULN
- ALT & AST<2.5 x ULN
- INR<1.5 or PT/PTT within normal limits. Pts receiving anti-coagulation treatment w low-molecular weight heparin allowed to participate, oral warfarin is not permitted
- Creatinine<1.5 x ULN
- Serum Na, K+, Mg2+, Phosphate & Ca2+ >LLN
- Interval<2 wks between prior surgical resection & initiation of study regimen
- Interval <12 weeks from completion of standard, daily XRT, unless one of following occurs: new area of enhancement on MRI imaging that is outside XRT field; biopsy proven recurrent tumor; / radiographic evidence of progressive tumor on 2 consecutive scans >4 wks apart.
- Interval <4weeks from prior chemotherapy unless there is unequivocal evidence of tumor progression & pt has recovered from all anticipated toxicities from prior therapy
- Interval <4weeks from prior investigational agent unless there is unequivocal evidence of tumor progression & pt has recovered from all anticipated toxicities from prior therapy
- Signed written informed consent including HIPAA according to institutional guidelines. Signed informed consent must be obtained prior to any study specific procedures
- If sexually active, pts will take contraceptive measures for duration of treatments & for 4 weeks following discontinuation of dasatinib & Erlotinib.
- Women of childbearing potential must have negative serum or urine pregnancy test within 72 hrs prior to start of study drug administration
Exclusion Criteria:
- No prior dasatinib / oral EGFR-inhibitor therapy
- Pregnancy/breast feeding
History of significant concurrent illness
->3 prior episodes of progressive disease
- Significant cardiac disease
- Excessive risk of bleeding as defined by stroke <6 months, history of CNS / intraocular bleed,/ septic endocarditis.
- Concurrent severe and/or uncontrolled medical disease that could compromise participation in study including any of following: pleural / pericardial effusion of any grade; uncontrolled diabetes; uncontrolled hypertension; active clinically serious infection >CTCAEv3 Gr2 requiring active intervention; history of clinically-significant bleeding diathesis or coagulopathy including platelet function disorder or acquired bleeding disorder within 1yr; impairment of GI function /GI disease that may significantly alter absorption of study regimen; ongoing or recent significant gastrointestinal bleeding
- Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks <6 months
- Any hemorrhage/bleeding event >CTCAEv3AE Gr3 within 4wks of 1st dose of study drug
- Serious non-healing wound, ulcer, /bone fracture
- Major surgery, open biopsy /significant traumatic injury <4 weeks of 1st study drug
- Known HIV infection/chronic Hepatitis B/C
- Pt is <3yrs free of another primary malignancy except: if other primary malignancy is either not currently clinically significant/does not require active intervention. Existence of any other malignant disease is not allowed.
- Pts unwilling to/unable to comply with protocol including ability to swallow whole pills/presence of any malabsorption syndrome
- Concurrent administration of warfarin, rifampin/St. John's Wort
- Subjects w hypokalemia/hypomagnesemia if it cannot be corrected
- Prisoners/subjects who are compulsorily detained for treatment of either psychiatric/physical illness
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Stratum A
Pts not on EIAEDs
|
You will begin study drug regimen on day 1 of cycle 1 w Dasatinib.
If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected.
Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule.
Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1.
If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1.
Both drugs will be given in continuous daily oral manner.
Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
Andre navn:
|
Eksperimentell: Stratum B
Pts on EIAEDs
|
You will begin study drug regimen on day 1 of cycle 1 w Dasatinib.
If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected.
Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule.
Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1.
If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1.
Both drugs will be given in continuous daily oral manner.
Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To determine MTD & DLT of Dasatinib when combined w Erlotinib among pts w Recurrent MG
Tidsramme: 12 months
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
To further evaluate safety & tolerability of Dasatinib + Erlotinib
Tidsramme: 12 months
|
12 months
|
To evaluate the PK of Dasatinib when administered w Erlotinib among Recurrent MG pts who are on & not on EIAEDs
Tidsramme: 12 months
|
12 months
|
To evaluate for anti-tumor activity w this regimen in this pt population
Tidsramme: 12 months
|
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer, kjertel og epitel
- Astrocytom
- Glioma
- Neoplasmer, Neuroepithelial
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Glioblastom
- Gliosarkom
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Proteinkinasehemmere
- Erlotinib hydroklorid
- Dasatinib
Andre studie-ID-numre
- Pro00002272
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Glioblastom
-
Celldex TherapeuticsFullførtGlioblastom | Gliosarkom | Tilbakevendende glioblastom | Småcellet glioblastom | Kjempecelleglioblastom | Glioblastom med oligodendroglial komponent | Tilbakefallende glioblastomForente stater
-
Northwestern UniversityNational Cancer Institute (NCI)RekrutteringGlioblastom | Astrocytom | Tilbakevendende glioblastom | MGMT-Umetylert glioblastom | Glioblastom, IDH-villtypeForente stater
-
Istituto Oncologico Veneto IRCCSBayer S.p.ARekrutteringGlioblastom, IDH-villtype | MGMT-metylert glioblastomItalia
-
Northwestern UniversityNational Cancer Institute (NCI); Moleculin Biotech, Inc.RekrutteringMGMT-Umetylert glioblastom | Glioblastom, IDH-villtypeForente stater
-
Vastra Gotaland RegionKarolinska Institutet; Oslo University Hospital; Aarhus University Hospital; Sahlgrenska University Hospital, Sweden og andre samarbeidspartnereHar ikke rekruttert ennåGlioblastom, IDH-villtype | MGMT-metylert glioblastom
-
Massachusetts General HospitalHar ikke rekruttert ennåGlioblastom tilbakevendende, EGFR vIII mutant | Nydiagnostisert glioblastom, EGFRvIII-mutant | Tilbakevendende glioblastom, EGFR vIII negativForente stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringTilbakevendende glioblastom | Ildfast glioblastomForente stater
-
Northwestern UniversityAgenus Inc.; CarTheraRekrutteringGlioblastoma Multiforme | Gliosarkom | Nylig diagnostisert glioblastom | Glioblastom, isositrisk dehydrogenase (IDH)-villtypeForente stater
-
Celldex TherapeuticsFullførtGlioblastom | Gliosarkom | Småcellet glioblastom | Kjempecelleglioblastom | Glioblastom med oligodendroglial komponentForente stater, Canada, Australia, Israel, Taiwan, Storbritannia, Belgia, Frankrike, Spania, Tyskland, Østerrike, Brasil, Colombia, Tsjekkia, Hellas, Ungarn, India, Italia, Mexico, Nederland, New Zealand, Peru, Sveits, Thailand
-
National Cancer Institute (NCI)SuspendertTilbakevendende glioblastom, IDH-Wildtype | MGMT-metylert glioblastom | Tilbakevendende MGMT-metylert glioblastomForente stater
Kliniske studier på Erlotinib and Dasatinib
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbFullførtIkke-småcellet lungekarsinomForente stater
-
M.D. Anderson Cancer CenterBristol-Myers Squibb; OSI PharmaceuticalsFullførtIkke-småcellet lungekreft | LungekreftForente stater
-
M.D. Anderson Cancer CenterFullført
-
Gustave Roussy, Cancer Campus, Grand ParisInnovative Therapies For Children with Cancer ConsortiumUkjentDiffus Intrinsic Pontine GliomaFrankrike
-
University of PittsburghFullførtHode- og nakkekreft | Ikke småcellet lungekreftForente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk bukspyttkjerteladenokarsinom | Tilbakevendende bukspyttkjertelkarsinom | Stage III Bukspyttkjertelkreft AJCC v6 og v7 | Stage IV Bukspyttkjertelkreft AJCC v6 og v7Forente stater
-
University Hospitals Cleveland Medical CenterUkjentAstma | Allergisk rhinitt | Allergisk konjunktivittForente stater
-
Bristol-Myers SquibbFullførtFarmakokinetisk studie hos friske deltakereForente stater
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Fullført
-
Hyoung Jin KangHar ikke rekruttert ennåAkutt lymfatisk leukemi, pediatrisk